Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
CATX
$5.42
$
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Next Earnings
2026-02-25
Beta
1.786
Average Volume
Market Cap
Last Dividend
CIK
0000728387
ISIN
US46489V3024
CUSIP
46489V302
CEO
Johan Spoor
Sector
Healthcare
Industry
Medical - Devices
Full Time Employees
138
IPO Date
2005-11-10
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| New Treatment Modalities Are Reaching Cancers That Resisted Everything Else | /PRNewswire/ -- Equity-Insider.com News Commentary - More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies | PRNewsWire | 2026-02-17 11:17:00 |
| Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results | SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its full year 2025 financial results and provide a business update on Monday, March 16, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases. | GlobeNewsWire | 2026-02-17 07:00:00 |
| Profusa (NASDAQ:PFSA) and Perspective Therapeutics (NASDAQ:CATX) Financial Contrast | Perspective Therapeutics (NASDAQ: CATX - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability. Insider and Institutional Ownership 54.7% of Perspective Therapeutics | Defense World | 2026-02-07 01:08:45 |
| Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants | SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced the pricing of an underwritten offering of 39,576,088 shares of its common stock at an offering price of $3.79 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 6,598,046 shares of its common stock at a price of $3.789 per pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $175 million, before deducting underwriting discounts and commissions and other offering expenses payable by Perspective in connection with the offering. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, minus the $0.001 per share exercise price of such pre-funded warrant. The offering is expected to close on or about February 3, 2026, subject to the satisfaction of customary closing conditions. All of the shares of common stock and pre-funded warrants to be sold in the offering are being sold by Perspective. | GlobeNewsWire | 2026-02-02 08:35:00 |
| Comparing Perspective Therapeutics (NASDAQ:CATX) & Biosig Technologies (NASDAQ:STEX) | Biosig Technologies (NASDAQ: STEX - Get Free Report) and Perspective Therapeutics (NASDAQ: CATX - Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends. Valuation and Earnings This table compares Biosig | Defense World | 2026-02-02 02:00:56 |
| Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space | Perspective Therapeutics, Inc. retains a Strong Buy rating, driven by promising VMT-a-NET data and Sanofi deprioritizing a competing SSTR2-targeted therapy. CATX's VMT-a-NET achieved 76% progression-free and alive status in SSTR2 NET patients, with pivotal mid-2026 data readouts expected to drive further value. Upcoming catalysts include full 48-week cohort 2 data, higher-dose cohort 3 results, and additional pipeline readouts for VMT01 and PSV359 in 2026. | Seeking Alpha | 2026-01-30 15:37:07 |
| Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Down 4.4% – Time to Sell? | Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report)'s share price traded down 4.4% during trading on Monday. The stock traded as low as $2.58 and last traded at $2.59. 732,483 shares changed hands during mid-day trading, a decline of 36% from the average session volume of 1,137,457 shares. The stock had previously closed at | Defense World | 2026-01-27 03:30:46 |
| Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Seeking Alpha | 2026-01-14 21:46:01 |
| Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium | SEATTLE, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body, announced updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs) are being presented as a poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO-GI), taking place January 8-10 in San Francisco, CA. | GlobeNewsWire | 2026-01-09 07:00:00 |
| Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of “Buy” by Brokerages | Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) have been assigned a consensus rating of "Buy" from the ten brokerages that are presently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company. The average | Defense World | 2026-01-04 01:55:06 |
| Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14, 2026, at 2:15 p.m. PT. | GlobeNewsWire | 2025-12-18 07:00:00 |
| Critical Survey: Perspective Therapeutics (NASDAQ:CATX) & Vyome (NASDAQ:HIND) | Vyome (NASDAQ: HIND - Get Free Report) and Perspective Therapeutics (NASDAQ: CATX - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership. Institutional and Insider Ownership 22.1% of Vyome shares | Defense World | 2025-12-14 01:59:14 |
| Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of “Buy” from Brokerages | Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) have been given an average recommendation of "Buy" by the ten analysts that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation and four have given a strong buy recommendation to the company. The average 12-month | Defense World | 2025-12-10 01:46:50 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G | 2026-02-12 | 2026-02-12 | View Filing |
| SC 13G | 2026-02-09 | 2026-02-09 | View Filing |
| SC 13G | 2026-02-06 | 2026-02-06 | View Filing |
| SC 13G | 2026-02-05 | 2026-02-05 | View Filing |
| 8-K | 2026-02-03 | 2026-02-03 | View Filing |
| 424B5 | 2026-02-03 | 2026-02-02 | View Filing |
| FWP | 2026-02-02 | 2026-02-02 | View Filing |
| 8-K | 2026-02-02 | 2026-02-02 | View Filing |
| 8-K | 2026-01-14 | 2026-01-14 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| 8-K | 2026-01-09 | 2026-01-09 | View Filing |
| SC 13G/A | 2025-12-05 | 2025-12-05 | View Filing |
| 8-K | 2025-12-01 | 2025-12-01 | View Filing |
| 4 | 2025-11-17 | 2025-11-17 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-10 | 2025-11-10 | View Filing |
| 8-K | 2025-11-10 | 2025-11-10 | View Filing |
| SC 13G/A | 2025-11-07 | 2025-11-07 | View Filing |
| 8-K | 2025-11-06 | 2025-11-06 | View Filing |
| 8-K | 2025-11-03 | 2025-11-03 | View Filing |
| 8-K | 2025-10-20 | 2025-10-20 | View Filing |
| 8-K | 2025-10-01 | 2025-10-01 | View Filing |
| 4 | 2025-09-05 | 2025-09-05 | View Filing |
| 3 | 2025-09-05 | 2025-09-05 | View Filing |
| 4 | 2025-09-05 | 2025-09-05 | View Filing |
| 3 | 2025-09-05 | 2025-09-05 | View Filing |
| 8-K | 2025-09-04 | 2025-09-04 | View Filing |
| 8-K | 2025-09-03 | 2025-09-03 | View Filing |
| 8-K | 2025-09-02 | 2025-09-02 | View Filing |
| 10-Q | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-01 | 2025-08-01 | View Filing |
| 8-K | 2025-07-03 | 2025-07-03 | View Filing |
| 8-K | 2025-06-23 | 2025-06-23 | View Filing |
| 8-K | 2025-06-03 | 2025-06-03 | View Filing |
| 8-K | 2025-05-30 | 2025-05-30 | View Filing |
| 8-K | 2025-05-28 | 2025-05-28 | View Filing |
| SD | 2025-05-19 | 2025-05-19 | View Filing |
| 10-Q | 2025-05-12 | 2025-05-12 | View Filing |
| 8-K | 2025-05-12 | 2025-05-12 | View Filing |
| 8-K | 2025-05-01 | 2025-05-01 | View Filing |
| 8-K | 2025-04-29 | 2025-04-29 | View Filing |
| DEFA14A | 2025-04-16 | 2025-04-16 | View Filing |
| DEF 14A | 2025-04-16 | 2025-04-16 | View Filing |
| 8-K | 2025-04-11 | 2025-04-11 | View Filing |
| EFFECT | 2025-04-09 | 2025-04-09 | View Filing |
| POS AM | 2025-04-04 | 2025-04-04 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 10-K/A | 2025-03-28 | 2025-03-28 | View Filing |
| S-8 | 2025-03-26 | 2025-03-27 | View Filing |
| POS AM | 2025-03-26 | 2025-03-26 | View Filing |
| 10-K | 2025-03-26 | 2025-03-26 | View Filing |
| 8-K | 2025-03-26 | 2025-03-26 | View Filing |
| POSASR | 2025-03-26 | 2025-03-26 | View Filing |
| 8-K | 2025-03-17 | 2025-03-17 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 8-K | 2025-03-04 | 2025-03-04 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| 8-K | 2025-02-03 | 2025-02-03 | View Filing |
| 8-K | 2025-01-24 | 2025-01-24 | View Filing |
| 8-K | 2025-01-13 | 2025-01-13 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 3 | 2025-01-07 | 2025-01-07 | View Filing |
| 8-K | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2024-12-06 | 2024-12-06 | View Filing |
| 4 | 2024-12-04 | 2024-12-04 | View Filing |
| 4/A | 2024-12-04 | 2024-12-04 | View Filing |
| 4/A | 2024-12-04 | 2024-12-04 | View Filing |
| 8-K | 2024-12-04 | 2024-12-03 | View Filing |
| 4 | 2024-11-27 | 2024-11-27 | View Filing |
| 4 | 2024-11-27 | 2024-11-27 | View Filing |
| 4 | 2024-11-26 | 2024-11-26 | View Filing |
| 8-K | 2024-11-21 | 2024-11-21 | View Filing |
| 8-K | 2024-11-15 | 2024-11-15 | View Filing |
| SC 13G | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G | 2024-11-08 | 2024-11-08 | View Filing |
| SC 13G/A | 2024-11-07 | 2024-11-07 | View Filing |
| SC 13G | 2024-11-07 | 2024-11-07 | View Filing |
| SC 13G | 2024-10-24 | 2024-10-24 | View Filing |
| 8-K | 2024-10-11 | 2024-10-11 | View Filing |
| 8-K | 2024-09-20 | 2024-09-20 | View Filing |
| 8-K | 2024-09-05 | 2024-09-05 | View Filing |
| 8-K | 2024-08-30 | 2024-08-30 | View Filing |
| 8-K | 2024-08-19 | 2024-08-19 | View Filing |
| S-8 | 2024-08-14 | 2024-08-13 | View Filing |
| 8-K | 2024-08-13 | 2024-08-13 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|